ChemGenex Pharmaceuticals Limited Launches Multinational Phase 2/3 Study For CML Patients With The T315I Mutation

MELBOURNE, Australia, & MENLO PARK, Calif.--(BUSINESS WIRE)--June 13, 2006--ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announced today that it has launched a new multi-national phase 2/3 study evaluating the use of CeflatoninĀ® (homoharringtonine, HHT) in patients with chronic, accelerated and blast-phase chronic myeloid leukemia (CML) who have the T315I bcr-abl point mutation, which is associated with resistance to GleevecĀ® and two known tyrosine kinase inhibitors (TKIs) currently under development.

Back to news